• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

相似文献

1
The perils of PCR: can we accurately 'correct' antimalarial trials?PCR 的风险：我们能准确“纠正”抗疟试验吗？
Trends Parasitol. 2010 Mar;26(3):119-24. doi: 10.1016/j.pt.2009.12.007. Epub 2010 Jan 18.
2
Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.在流行地区，服用抗叶酸抗疟药物的人群中，叶酸补充剂与疟疾易感性和严重程度的关系。
Cochrane Database Syst Rev. 2022 Feb 1;2(2022):CD014217. doi: 10.1002/14651858.CD014217.
3
Some considerations in the design and interpretation of antimalarial drug trials in uncomplicated falciparum malaria.非复杂性恶性疟原虫疟疾抗疟药物试验设计与解读中的一些考量因素。
Malar J. 2006 Dec 22;5:127. doi: 10.1186/1475-2875-5-127.
4
Uncertain outcomes: adjusting for misclassification in antimalarial efficacy studies.不确定的结果：在抗疟疗效研究中调整分类错误。
Epidemiol Infect. 2011 Apr;139(4):544-51. doi: 10.1017/S0950268810001652. Epub 2010 Jul 12.
5
PCR correction strategies for malaria drug trials: updates and clarifications.疟疾药物试验的 PCR 校正策略：更新与澄清。
Lancet Infect Dis. 2020 Jan;20(1):e20-e25. doi: 10.1016/S1473-3099(19)30426-8. Epub 2019 Sep 17.
6
Evaluating the pharmacodynamic effect of antimalarial drugs in clinical trials by quantitative PCR.通过定量PCR评估抗疟药物在临床试验中的药效学作用。
Antimicrob Agents Chemother. 2015 Jul;59(7):4249-59. doi: 10.1128/AAC.04942-14. Epub 2015 May 11.
7
Effectiveness of artemisinin-based combination therapy used in the context of home management of malaria: a report from three study sites in sub-Saharan Africa.基于青蒿素的联合疗法在疟疾家庭管理中的有效性：撒哈拉以南非洲三个研究地点的报告。
Malar J. 2008 Sep 27;7:190. doi: 10.1186/1475-2875-7-190.
8
Atovaquone-proguanil for treating uncomplicated Plasmodium falciparum malaria.阿托伐醌-磺胺多辛乙胺嘧啶片治疗无并发症恶性疟原虫疟疾。
Cochrane Database Syst Rev. 2021 Jan 15;1(1):CD004529. doi: 10.1002/14651858.CD004529.pub3.
9
Competing risk events in antimalarial drug trials in uncomplicated Plasmodium falciparum malaria: a WorldWide Antimalarial Resistance Network individual participant data meta-analysis.复杂 Plasmodium falciparum 疟疾的抗疟药物试验中的竞争风险事件：全球抗疟药物耐药性网络个体参与者数据荟萃分析。
Malar J. 2019 Jul 5;18(1):225. doi: 10.1186/s12936-019-2837-4.
10
Monitoring antimalarial safety and tolerability in clinical trials: a case study from Uganda.监测临床试验中抗疟药的安全性和耐受性：来自乌干达的一个案例研究。
Malar J. 2008 Jun 11;7:107. doi: 10.1186/1475-2875-7-107.

引用本文的文献

1
Impact of dhps mutations on sulfadoxine-pyrimethamine protective efficacy and implications for malaria chemoprevention.二氢蝶酸合酶（DHPS）突变对周效磺胺-乙胺嘧啶预防效果的影响及其对疟疾化学预防的意义。
Nat Commun. 2025 May 8;16(1):4268. doi: 10.1038/s41467-025-58326-z.
2
Persistent and multiclonal malaria parasite dynamics despite extended artemether-lumefantrine treatment in children.尽管延长了青蒿琥酯-咯萘啶治疗，但仍存在持续性和多克隆疟原虫动态。
Nat Commun. 2024 May 7;15(1):3817. doi: 10.1038/s41467-024-48210-7.
3
msp1, msp2, and glurp genotyping to differentiate Plasmodium falciparum recrudescence from reinfections during prevention of reestablishment phase, Sri Lanka, 2014-2019.2014 - 2019年斯里兰卡预防再感染阶段，采用msp1、msp2和glurp基因分型鉴别恶性疟原虫复发与再感染情况
Malar J. 2024 Jan 27;23(1):35. doi: 10.1186/s12936-024-04858-6.
4
The temporal dynamics of Plasmodium species infection after artemisinin-based combination therapy (ACT) among asymptomatic children in the Hohoe municipality, Ghana.加纳霍霍市无症状儿童使用青蒿素类复方疗法（ACT）后疟原虫感染的时间动态。
Malar J. 2023 Sep 14;22(1):271. doi: 10.1186/s12936-023-04712-1.
5
Persistent Submicroscopic Plasmodium falciparum Parasitemia 72 Hours after Treatment with Artemether-Lumefantrine Predicts 42-Day Treatment Failure in Mali and Burkina Faso.青蒿琥酯-咯萘啶治疗后 72 小时持续亚微观疟原虫血症可预测马里和布基纳法索 42 天治疗失败。
Antimicrob Agents Chemother. 2021 Jul 16;65(8):e0087321. doi: 10.1128/AAC.00873-21.
6
Increased Sensitivity of Plasmodium falciparum to Artesunate/Amodiaquine Despite 14 Years as First-Line Malaria Treatment, Zanzibar.尽管青蒿琥酯/阿莫地喹作为一线疟疾治疗药物已使用了 14 年，但在桑给巴尔，恶性疟原虫对其敏感性增加。
Emerg Infect Dis. 2020 Aug;26(8):1767-1777. doi: 10.3201/eid2608.191547.
7
Adherence to Mass Drug Administration with Dihydroartemisinin-Piperaquine and Clearance in Southern Province, Zambia.赞比亚南方省二氢青蒿素-哌喹全民服药治疗的依从性和清除率。
Am J Trop Med Hyg. 2020 Aug;103(2_Suppl):37-45. doi: 10.4269/ajtmh.19-0667.
8
A Computer Modelling Approach To Evaluate the Accuracy of Microsatellite Markers for Classification of Recurrent Infections during Routine Monitoring of Antimalarial Drug Efficacy.一种计算机建模方法，用于评估微卫星标记在常规抗疟药物疗效监测中对复发性感染分类的准确性。
Antimicrob Agents Chemother. 2020 Mar 24;64(4). doi: 10.1128/AAC.01517-19.
9
Amplicon deep sequencing improves Plasmodium falciparum genotyping in clinical trials of antimalarial drugs.扩增子深度测序提高了抗疟药物临床试验中恶性疟原虫的基因分型。
Sci Rep. 2019 Nov 28;9(1):17790. doi: 10.1038/s41598-019-54203-0.
10
Dealing with indeterminate outcomes in antimalarial drug efficacy trials: a comparison between complete case analysis, multiple imputation and inverse probability weighting.处理抗疟药物疗效试验中的不确定结局：完全病例分析、多重插补和逆概率加权法的比较。
BMC Med Res Methodol. 2019 Nov 27;19(1):215. doi: 10.1186/s12874-019-0856-z.

本文引用的文献

1
Artemisinin resistance in Plasmodium falciparum malaria.恶性疟原虫疟疾中的青蒿素耐药性。
N Engl J Med. 2009 Jul 30;361(5):455-67. doi: 10.1056/NEJMoa0808859.
2
Misclassification of drug failure in Plasmodium falciparum clinical trials in southeast Asia.东南亚恶性疟原虫临床试验中药物治疗失败的错误分类。
J Infect Dis. 2009 Aug 15;200(4):624-8. doi: 10.1086/600892.
3
Competitive facilitation of drug-resistant Plasmodium falciparum malaria parasites in pregnant women who receive preventive treatment.在接受预防性治疗的孕妇中，耐药恶性疟原虫疟疾寄生虫的竞争性促进作用。
Proc Natl Acad Sci U S A. 2009 Jun 2;106(22):9027-32. doi: 10.1073/pnas.0901415106. Epub 2009 May 18.
4
Novel pfdhps haplotypes among imported cases of Plasmodium falciparum malaria in the United Kingdom.英国输入性恶性疟原虫疟疾病例中的新型pfdhps单倍型
Antimicrob Agents Chemother. 2009 Aug;53(8):3405-10. doi: 10.1128/AAC.00024-09. Epub 2009 May 11.
5
Cross-sectional characterization of HIV-1 env compartmentalization in cerebrospinal fluid over the full disease course.在整个疾病过程中对脑脊液中 HIV-1 env 隔室化的横断面特征进行描述。
AIDS. 2009 May 15;23(8):907-15. doi: 10.1097/QAD.0b013e3283299129.
6
Novel dhps and pfcrt polymorphisms in Plasmodium falciparum detected by heteroduplex tracking assay.通过异源双链追踪分析检测到的恶性疟原虫新型二氢蝶酸合酶（DHPS）和氯喹抗性转运蛋白（Pfcrt）多态性
Am J Trop Med Hyg. 2009 May;80(5):734-6.
7
Optimization and validation of multi-coloured capillary electrophoresis for genotyping of Plasmodium falciparum merozoite surface proteins (msp1 and 2).用于恶性疟原虫裂殖子表面蛋白（msp1和msp2）基因分型的多色毛细管电泳的优化与验证
Malar J. 2009 Apr 23;8:78. doi: 10.1186/1475-2875-8-78.
8
Nonradioactive heteroduplex tracking assay for the detection of minority-variant chloroquine-resistant Plasmodium falciparum in Madagascar.用于检测马达加斯加少数变异型氯喹抗性恶性疟原虫的非放射性异源双链追踪分析
Malar J. 2009 Mar 16;8:47. doi: 10.1186/1475-2875-8-47.
9
Failure of artesunate-mefloquine combination therapy for uncomplicated Plasmodium falciparum malaria in southern Cambodia.青蒿琥酯-甲氟喹联合疗法治疗柬埔寨南部非复杂性恶性疟原虫疟疾失败。
Malar J. 2009 Jan 12;8:10. doi: 10.1186/1475-2875-8-10.
10
Extensive dynamics of Plasmodium falciparum densities, stages and genotyping profiles.恶性疟原虫密度、阶段和基因分型概况的广泛动态变化。
Malar J. 2008 Nov 21;7:241. doi: 10.1186/1475-2875-7-241.

PCR 的风险：我们能准确“纠正”抗疟试验吗？

The perils of PCR: can we accurately 'correct' antimalarial trials?

机构信息

Division of Infectious Diseases, Department of Medicine, University of North Carolina School of Medicine, Chapel Hill, NC 27599, USA.

出版信息

Trends Parasitol. 2010 Mar;26(3):119-24. doi: 10.1016/j.pt.2009.12.007. Epub 2010 Jan 18.

DOI:10.1016/j.pt.2009.12.007
PMID:20083436
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC2844636/
Abstract

During follow-up in antimalarial drug trials, treated subjects can be newly infected. PCR correction is used to distinguish this re-infection from drug failure (recrudescence) and to adjust final drug efficacy estimates. The epidemiological, biological and technical limitations of PCR correction and how this can lead to misclassification in drug trial outcomes are underappreciated. This article considers these limitations and proposes a framework for reporting, interpreting and improving PCR correction of antimalarial trials.

摘要

在抗疟药物试验的随访过程中，治疗对象可能会被新感染。聚合酶链反应（PCR）校正用于区分这种再感染和药物失败（复发），并调整最终药物疗效估计。PCR 校正的流行病学、生物学和技术局限性以及这如何导致药物试验结果的错误分类尚未得到充分认识。本文考虑了这些局限性，并提出了一个报告、解释和改进抗疟试验中 PCR 校正的框架。